UA107675C2 - Застосування n-(4-((3-(2-аміно-4-піримідиніл)-2-піридиніл)окси)феніл)-4-(4-метил-2-тієніл)-1-фталазинаміну для лікування раку, рефрактерного до лікування протираковим агентом - Google Patents

Застосування n-(4-((3-(2-аміно-4-піримідиніл)-2-піридиніл)окси)феніл)-4-(4-метил-2-тієніл)-1-фталазинаміну для лікування раку, рефрактерного до лікування протираковим агентом

Info

Publication number
UA107675C2
UA107675C2 UAA201204585A UAA201204585A UA107675C2 UA 107675 C2 UA107675 C2 UA 107675C2 UA A201204585 A UAA201204585 A UA A201204585A UA A201204585 A UAA201204585 A UA A201204585A UA 107675 C2 UA107675 C2 UA 107675C2
Authority
UA
Ukraine
Prior art keywords
treatment
thienyl
oxy
phenyl
amino
Prior art date
Application number
UAA201204585A
Other languages
English (en)
Russian (ru)
Ukrainian (uk)
Inventor
Marc Payton
Richard Kendall
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43216900&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA107675(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of UA107675C2 publication Critical patent/UA107675C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
UAA201204585A 2009-09-11 2010-09-09 Застосування n-(4-((3-(2-аміно-4-піримідиніл)-2-піридиніл)окси)феніл)-4-(4-метил-2-тієніл)-1-фталазинаміну для лікування раку, рефрактерного до лікування протираковим агентом UA107675C2 (xx)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24152709P 2009-09-11 2009-09-11
PCT/US2010/048247 WO2011031842A1 (en) 2009-09-11 2010-09-09 N-4 ( - ( ( 3- ( 2 -amino-4 pyrimidinyl) -2 -pyridinyl) oxy) phenyl) -4- (4-methyl-2-thienyl) -1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer

Publications (1)

Publication Number Publication Date
UA107675C2 true UA107675C2 (xx) 2015-02-10

Family

ID=43216900

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201204585A UA107675C2 (xx) 2009-09-11 2010-09-09 Застосування n-(4-((3-(2-аміно-4-піримідиніл)-2-піридиніл)окси)феніл)-4-(4-метил-2-тієніл)-1-фталазинаміну для лікування раку, рефрактерного до лікування протираковим агентом

Country Status (34)

Country Link
US (1) US20120028917A1 (cg-RX-API-DMAC7.html)
EP (2) EP2818170B1 (cg-RX-API-DMAC7.html)
JP (1) JP5851403B2 (cg-RX-API-DMAC7.html)
KR (1) KR20120082896A (cg-RX-API-DMAC7.html)
CN (1) CN102869361A (cg-RX-API-DMAC7.html)
AU (1) AU2010292225C1 (cg-RX-API-DMAC7.html)
BR (1) BR112012008325A2 (cg-RX-API-DMAC7.html)
CA (1) CA2773838C (cg-RX-API-DMAC7.html)
CL (1) CL2012000640A1 (cg-RX-API-DMAC7.html)
CR (1) CR20120171A (cg-RX-API-DMAC7.html)
DK (1) DK2475368T3 (cg-RX-API-DMAC7.html)
EA (1) EA020526B1 (cg-RX-API-DMAC7.html)
ES (1) ES2528485T3 (cg-RX-API-DMAC7.html)
HK (1) HK1205457A1 (cg-RX-API-DMAC7.html)
HR (1) HRP20150104T1 (cg-RX-API-DMAC7.html)
HU (1) HUE024568T2 (cg-RX-API-DMAC7.html)
IL (1) IL218569A0 (cg-RX-API-DMAC7.html)
MA (1) MA33658B1 (cg-RX-API-DMAC7.html)
ME (1) ME02048B (cg-RX-API-DMAC7.html)
MX (1) MX2012003041A (cg-RX-API-DMAC7.html)
NZ (1) NZ598758A (cg-RX-API-DMAC7.html)
PE (1) PE20120895A1 (cg-RX-API-DMAC7.html)
PH (1) PH12012500504A1 (cg-RX-API-DMAC7.html)
PL (1) PL2475368T3 (cg-RX-API-DMAC7.html)
PT (1) PT2475368E (cg-RX-API-DMAC7.html)
RS (1) RS53807B1 (cg-RX-API-DMAC7.html)
SG (1) SG179102A1 (cg-RX-API-DMAC7.html)
SI (1) SI2475368T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201500028B (cg-RX-API-DMAC7.html)
TN (1) TN2012000110A1 (cg-RX-API-DMAC7.html)
TW (1) TW201121956A (cg-RX-API-DMAC7.html)
UA (1) UA107675C2 (cg-RX-API-DMAC7.html)
WO (1) WO2011031842A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201202472B (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013181462A1 (en) * 2012-05-31 2013-12-05 Amgen Inc. Use of amg 900 for the treatment of cancer
CN103664737A (zh) * 2012-09-25 2014-03-26 杨子娇 一类治疗房角狭窄的化合物及其用途
KR101701235B1 (ko) 2013-09-30 2017-02-03 한국원자력의학원 Hrp-3 억제제를 포함하는 방사선 또는 약물내성 암의 치료용 약학 조성물
MY192088A (en) 2013-11-11 2022-07-26 Amgen Inc Combinantion therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
SG11201604517WA (en) 2013-12-03 2016-07-28 Amgen Inc Crystalline forms of n-(4-((3-(2-amino-4-pyrimidinyl) - 2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1 -phthalazinamine pharmaceutically acceptable salts and uses thereof
BR112016019161B1 (pt) * 2014-02-21 2022-12-20 Frost Biologic, Inc Amidas antimitóticas, composições farmacêuticas que as compreendem e uso das mesmas
WO2017181087A1 (en) * 2016-04-15 2017-10-19 Felicitex Therapeutics, Inc. Combinations for the treatment of neoplasms using quiescent cell targeting and inhibitors of mitosis
UA127968C2 (uk) 2017-05-22 2024-02-28 Емджен Інк. Інгібітори g12c kras і способи їх застосування
US10640504B2 (en) 2017-09-08 2020-05-05 Amgen Inc. Inhibitors of KRAS G12C and methods of using the same
MX2020010836A (es) 2018-05-04 2021-01-08 Amgen Inc Inhibidores de kras g12c y métodos para su uso.
AU2019284472B2 (en) 2018-06-11 2024-05-30 Amgen Inc. KRAS G12C inhibitors for treating cancer
JP7369719B2 (ja) 2018-06-12 2023-10-26 アムジエン・インコーポレーテツド KRas G12C阻害剤及びそれを使用する方法
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法
EP3972973A1 (en) 2019-05-21 2022-03-30 Amgen Inc. Solid state forms

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003304266A1 (en) * 2003-07-03 2005-01-21 Cambridge University Technical Services Ltd Use of aurora kinase inhibitors for reducing the resistance of cancer cells
US7560551B2 (en) * 2006-01-23 2009-07-14 Amgen Inc. Aurora kinase modulators and method of use
EA018128B1 (ru) * 2006-01-23 2013-05-30 Амген Инк. Модуляторы аурора киназы, способы их получения и их применение
UA93538C2 (en) * 2006-01-23 2011-02-25 Амген Инк. Aurora kinase modulators and method of use
GB0609619D0 (en) * 2006-05-16 2006-06-21 Astrazeneca Ab Combination
GB0609621D0 (en) * 2006-05-16 2006-06-21 Astrazeneca Ab Novel co-crystal

Also Published As

Publication number Publication date
HK1173655A1 (en) 2013-05-24
ZA201202472B (en) 2012-12-27
US20120028917A1 (en) 2012-02-02
CA2773838C (en) 2016-05-31
HRP20150104T1 (xx) 2015-03-13
EP2818170B1 (en) 2018-12-05
MX2012003041A (es) 2012-06-27
PL2475368T3 (pl) 2015-05-29
KR20120082896A (ko) 2012-07-24
EA020526B1 (ru) 2014-11-28
PT2475368E (pt) 2015-02-10
AU2010292225B2 (en) 2012-12-13
CL2012000640A1 (es) 2012-09-21
CR20120171A (es) 2012-08-09
EP2818170A1 (en) 2014-12-31
SMT201500028B (it) 2015-03-05
HK1205457A1 (en) 2015-12-18
EA201270383A1 (ru) 2013-04-30
MA33658B1 (fr) 2012-10-01
AU2010292225C1 (en) 2013-06-27
CA2773838A1 (en) 2011-03-17
ES2528485T3 (es) 2015-02-10
WO2011031842A1 (en) 2011-03-17
ME02048B (me) 2015-05-20
EP2475368B1 (en) 2014-12-17
IL218569A0 (en) 2012-05-31
AU2010292225A1 (en) 2012-04-12
NZ598758A (en) 2013-12-20
DK2475368T3 (en) 2015-03-09
EP2475368A1 (en) 2012-07-18
SI2475368T1 (sl) 2015-03-31
HUE024568T2 (hu) 2016-02-29
JP5851403B2 (ja) 2016-02-03
CN102869361A (zh) 2013-01-09
JP2013504582A (ja) 2013-02-07
TN2012000110A1 (en) 2013-09-19
RS53807B1 (sr) 2015-06-30
PH12012500504A1 (en) 2015-04-29
TW201121956A (en) 2011-07-01
SG179102A1 (en) 2012-04-27
PE20120895A1 (es) 2012-08-19
BR112012008325A2 (pt) 2017-08-29

Similar Documents

Publication Publication Date Title
EA201270383A1 (ru) Применение n-(4-((3-(2-амино-4-пиримидинил)-2-пиридинил)окси)фенил)-4-(4-метил-2-тиенил)-1-фталазинамина для лечения резистентного к антимитотическому агенту рака
EA200971051A1 (ru) Ингибиторы p70 s6 киназы
UA94129C2 (ru) Соединения для ингибирования митоза
WO2007095124A3 (en) Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors
AU2011297889A8 (en) Pharmaceutically active compounds as Axl inhibitors
MX2012013197A (es) Inhibidores de indazol de cinasa.
EA200971115A1 (ru) Новые ингибиторы обратной транскриптазы вич
MX2009007944A (es) Compuestos y composiciones de purina como inhibidores de quinasa para el tratamiento de enfermedades relacionadas con plasmodium.
EA201001687A1 (ru) Производные имидазопиридина в качестве ингибиторов активиноподобной рецепторной киназы ( alk-4 или alk-5 )
WO2009155121A3 (en) Inhibitors of pi3 kinase
PT1940839E (pt) Inibidores de piridopirimidinona pi3k alfa
UA108369C2 (uk) Піролопіримідини як інгібітори cdk4/6
EA201100580A1 (ru) Имидазопиридазинкарбонитрилы, используемые в качестве ингибиторов киназы
MX2013007336A (es) Compuestos de bi-heteroarilo como inhibidores de vps34.
EA201071224A1 (ru) Ингибиторы limk2, композиции, содержащие их, и способы их применения
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
TN2011000207A1 (en) Akt and p70 s6 kinase inhibitors
MY150214A (en) Kinesin inhibitors as cancer therapeutics
EA201391629A1 (ru) Ингибиторы цсж-1r для лечения опухолей головного мозга
ATE542800T1 (de) Kinasehemmer und ihre anwendungsverfahren
MX2014005715A (es) N-metil-2-[3-((e)-2-piridin-2-il-vinil)-1h-indazol-6-ilsulfanil]- benzamida para el tratamiento de leucemia mielogenosa cronica.
ATE548364T1 (de) Aminopyrazolkinasehemmer
GEP20146025B (en) Chromenone derivatives as trpv3 antagonists
MY150776A (en) Combination of a bis-thiazolium salt or a precursor thereof and artemisinin or a derivative thereof for treating acute malaria
MX2018001306A (es) Compuestos de 4-(3-pirazolilamino)-bencimidazol y su uso como inhibidores jak1.